Key result
Early statin initiation in type 2 diabetes is linked to ~15% lower 10-year dementia risk.
Why the study?
Dementia burden is projected to rise, particularly in individuals with diabetes, but effective treatments are lacking and the association between early statin initiation and dementia risk was uncertain.
Is early initiation of statin therapy within 1 year of type 2 diabetes diagnosis associated with a lower 10-year risk of all-cause dementia compared with late initiation (1–5 years) or no statin initiation in statin-naïve adults?
Cohort (n=132,585)
Yes
Is early initiation of statin therapy within 1 year of type 2 diabetes diagnosis associated with a lower 10-year risk of all-cause dementia compared with late initiation (1–5 years) or no statin initiation in statin-naïve adults?
Answers are grounded in this paper and cite their sources.
Early initiation of statin therapy within one year of a type 2 diabetes diagnosis is associated with a lower 10-year risk of all-cause and vascular-related dementia compared to delayed or no statin initiation, reinforcing the importance of overcoming treatment inertia in newly diagnosed diabetes.
Summary: Background: The burden of dementia is projected to rise with aging populations, particularly in those with diabetes; however, there are no effective treatments, and attention has turned to prevention through treatment of modifiable risk factors such as low-density lipoprotein cholesterol. We tested the hypothesis that early initiation of statin treatment following type 2 diabetes diagnosis is associated with lower risk of all-cause dementia than delayed or no initiation. Methods: Using nationwide registers, we identified 132,585 statin-naïve individuals in Denmark developing type 2 diabetes from 2006 through 2019. Follow-up was until dementia, death, emigration, or December 31, 2021. Using a clone-censor weighting design emulating a target trial we compared: i) no statin within 5 years after diagnosis (reference), ii) late statin (start at 1–5 years), and iii) early statin (start at ≤ 1 year). The primary outcome was 10-year risk of all-cause dementia based on Aalen-Johansen survival curves with death treated as competing risk. Findings: During median 7.1 years of follow-up (interquartile range: 3.8–9.9 years), 3592/132,585 = 2.7% developed dementia. Estimated 10-year absolute risks of dementia from the weighted Aalen-Johansen analysis were 3.9% in those with no statin initiation, 3.3% in those with early statin initiation, and 3.5% in those with late statin initiation. Following diabetes diagnosis and compared to no statin initiation, early statin treatment was associated with 15% lower relative risk of dementia at 10 years (95% confidence interval: 9%–21%) while the corresponding relative risk for late statin treatment was 10% lower (3%–15%). Corresponding absolute risk differences were 0.59% (0.34%–0.86%) and 0.38% (0.12%–0.61%) lower, respectively. Interpretation: In statin-naïve individuals developing type 2 diabetes, statin therapy was associated with lower relative and absolute risks of dementia, most pronounced in those with early statin initiation. There is a need for trial evidence to confirm the findings.
No takes yet. Share an insight, caveat, or question.
Ternhamar et al. (2026) conducted a cohort in Incident type 2 diabetes (n=132,585). Early statin initiation (≤1 year after diabetes diagnosis) or late statin initiation (1–5 years after diagnosis) vs. No statin initiation within 5 years after diabetes diagnosis was evaluated on 10-year risk of all-cause dementia (RR 0.85 (15% lower relative risk) and ARR 0.59% for early statin initiation vs no statin, 95% CI 0.79-0.91, p=<0.001). Early statin initiation within 1 year of type 2 diabetes diagnosis was associated with a 15% lower 10-year relative risk of all-cause dementia compared to no statin.
Synapse has enriched 10 related papers. Consider them for comparative context: